The efficacy of reperfusion therapy (RT) using intravenous infusion of recombinant tissue plasminogen activator and/or endovascular therapy for minor ischemic stroke (MIS) has not yet been established. The present study aimed to elucidate the clinical features of MIS patients with atrial fibrillation (AF) and examine whether they could be potential candidates for RT. Data of MIS patients, defined as those with a score ≤ 5 on the National Institute of Health Stroke Scale, were extracted from patients admitted to our hospital between 2006 and 2018, and clinical characteristics were compared between the AF and non-AF groups. Thereafter, the impact of RT on outcomes in the AF- group was evaluated using the modified Rankin scale (mRS) score 3 months after onset and compared to that of standard medical therapy (SMT) using propensity score matching (PSM). Of 10,483 stroke patients, 3003 were shortlisted, and 457 AF patients and 2546 non-AF patients were finally selected. Patients in the AF group had more RT (13.3% vs. 5.7%, p < 0.001) than those in the non-AF group. Using PSM, 53 patients each were extracted from the AF-RT and AF-SMT groups. The frequencies of mRS = 0 or 1 for the AF-RT and AF-SMT groups were 69.8% and 64.2% (p = 0.536), respectively, with a significant difference in mRS = 0 (56.5% vs. 34.0%, p = 0.019). The present study found that MIS patients with AF underwent more RT than those without AF and that RT compared favorably with SMT for them; further study is warranted to examine whether these patients could be good candidates for RT.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price includes VAT (USA)
Tax calculation will be finalised during checkout.
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581–1587
Hacke W, Kaste M, Bluhmki E et al (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359:1317–1329
Furlan A, Higashida R, Wechsler L et al (1999) Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 282:2003–2011
Goyal M, Menon BK, van Zwam WH et al (2016) Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 387:1723–1731
Nogueira RG, Jadhav AP, Haussen DC et al (2018) Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 378:11–21
Albers GW, Marks MP, Kemp S et al (2018) Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med 378:708–718
Powers WJ, Rabinstein AA, Teri Ackerson T et al (2018) 2018 Guidelines for the early management of patients with acute ischemic stroke. a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 49:e46–e110
Reeves M, Khoury J, Alwell K et al (2013) Distribution of National Institutes of Health stroke scale in the Cincinnati/Northern Kentucky Stroke Study. Stroke 44:3211–3213
Khatri P, Conaway MR, Johnston KC et al (2012) Acute Stroke Accurate Prediction Study (ASAP) Investigators. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke. Stroke 43:560–562
Yeo LLL, Ho R, Paliwal P et al (2014) Intravenously administered tissue plasminogen activator useful in milder strokes? A meta-analysis. J Stroke Cerebrovasc Dis 23:2156–2162
Steger C, Pratter A, Martinek-Bregel M et al (2004) Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry. Eur Heart J 25:1734–1740
Park HK, Kim BJ, Han MK et al (2017) One-year outcomes after minor stroke or high-risk transient ischemic attack: Korean Multicenter Stroke Registry Analysis. Stroke 48:2991–2998
Yamaguchi T, Mori E, Minematsu K et al (2006) Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 37:1810–1815
Minematsu K, Toyoda K, Hirano T et al (2013) Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society. J Stroke Cerebrovasc Dis 22:571–600
Zaidat OO, Yoo AJ, Khatri P et al (2013) Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. Stroke 44:2650–2663
Smith EE, Fonarow GC, Reeves MJ et al (2011) Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke. Stroke 42:3110–3115
Chen W, Pan Y, Zhao X et al (2017) Intravenous thrombolysis in Chinese patients with different subtype of mild stroke: thrombolysis in patients with mild stroke. Sci Rep 23:2299. https://doi.org/10.1038/s41598-017-02579-2
Alkhouli M, Alqahtani F, Aljohani S et al (2018) Burden of atrial fibrillation-associated ischemic stroke in the United States. JACC Clin Electrophysiol 4:618–625
Wu L, Wang A, Wang X et al (2015) Factors for short-term outcomes in patients with a minor stroke: results from China National Stroke Registry. BMC Neurol 15:253. https://doi.org/10.1186/s12883-015-0505-z
Conflicts of interest:
All the authors declared that they have no conflict of interest.
Ethics approval: The study protocol was approved by our institutional review board.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Nomura, E., Takemaru, M., Himeno, T. et al. Clinical features and efficacy of reperfusion therapy in minor ischemic stroke patients with atrial fibrillation. J Thromb Thrombolysis 50, 608–613 (2020). https://doi.org/10.1007/s11239-020-02057-z
- Atrial fibrillation
- Endovascular therapy
- Minor ischemic stroke
- Reperfusion therapy
- Tissue-type plasminogen activator